摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate | 93851-87-7

中文名称
——
中文别名
——
英文名称
(RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate
英文别名
(RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]-morpholine;reboxetine;2-[α-(2-ethoxyphenoxy)benzyl]morpholine mesylate;Edronax;2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid
(RS)-2-[(RS)-α-(2-ethoxyphenoxy)benzyl]morpholine methanesulphonate化学式
CAS
93851-87-7
化学式
CH4O3S*C19H23NO3
mdl
——
分子量
409.503
InChiKey
CGTZMJIMMUNLQD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    103
  • 氢给体数:
    2
  • 氢受体数:
    7

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用总结:美国食品药品监督管理局尚未批准瑞波西汀在美国市场销售,但在其他国家瑞波西汀可购。有限信息表明,母亲每日剂量高达10毫克的瑞波西汀在母乳中产生的水平较低,似乎不会对哺乳婴儿产生任何不良反应。在更多数据可用之前,瑞波西汀在哺乳期间应谨慎使用并进行严密监测。 ◉ 对哺乳婴儿的影响:有4名患有产后抑郁症的母亲的婴儿在母亲接受瑞波西汀治疗期间(剂量不详)哺乳了1.3到2.1个月,平均剂量为每日6.5毫克(79微克/千克)。其中一名母亲还服用了每日20毫克的艾司西酞普兰,另一名母亲服用了每日300毫克的舍曲林。这些婴儿中没有表现出任何不良反应。其中三名婴儿的丹佛发展评分正常;第四名婴儿的发展年龄仅为正常的71%,但问题出现在母亲服用瑞波西汀之前。 ◉ 对泌乳和母乳的影响:瑞波西汀增加了男性受试者的血清催乳素水平。这一发现对哺乳母亲的意义尚不清楚。对于已经建立泌乳的母亲,催乳素水平可能不会影响她的哺乳能力。 ◉ 对哺乳的影响和结果:一项观察性研究调查了在怀孕前两年内服用抗抑郁药的2859名女性的结果。与怀孕期间未服用抗抑郁药的女性相比,整个孕期(三个季度)都服用抗抑郁药的母亲在出院时哺乳的可能性降低了37%。仅在第三季度服用抗抑郁药的母亲在出院时哺乳的可能性降低了75%。仅在第一季度和第二季度服用抗抑郁药的母亲在出院时哺乳的可能性没有降低。研究中并未指明母亲使用的具体抗抑郁药。 ◉ 一项回顾性队列研究比较了2001年至2008年的医院电子医疗记录,研究了在晚期妊娠期间被开出抗抑郁药的妇女(n = 575)与患有精神疾病但未接受抗抑郁药治疗的妇女(n = 1552)以及没有精神疾病诊断的妇女(n = 30,535)。接受抗抑郁药治疗的妇女在出院时哺乳的可能性比没有精神疾病诊断的妇女低37%,但与未接受治疗的精神疾病母亲相比,哺乳的可能性没有降低。这些母亲中没有人在服用瑞波西汀。 ◉ 在1999年至2008年对80,882对挪威母婴对的研究中,有392名妇女报告在产后新开始使用抗抑郁药,有201名妇女报告从怀孕期间继续使用抗抑郁药。与未暴露的对照组相比,晚期妊娠使用抗抑郁药与哺乳开始的可能性降低7%有关,但对哺乳持续时间或专一性没有影响。与未暴露的对照组相比,新开始或重新开始使用抗抑郁药与在6个月时主要哺乳的可能性降低63%和任何哺乳的可能性降低51%有关,以及突然停止哺乳的风险增加2.6倍。具体抗抑郁药未提及。
◉ Summary of Use during Lactation:Reboxetine is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal doses of up to 10 mg daily produce low levels in milk and appear to not result in any adverse effects in breastfed infants. Until more data are available, reboxetine should be used with careful monitoring during breastfeeding. ◉ Effects in Breastfed Infants:Four infants whose mothers had postpartum depression had been breastfed (extent not stated) for 1.3 to 2.1 months during maternal reboxetine therapy at an average dose of 6.5 mg (79 mcg/kg) daily. One of the mothers was also taking escitalopram 20 mg daily and another was taking sertraline 300 mg daily. None of the infants exhibited any adverse reactions. Three of the infants had normal Denver developmental scores; the fourth whose mother was taking reboxetine had a developmental age of only 71% of normal, but the problem predated maternal reboxetine therapy. Five women used reboxetine during pregnancy and lactation (extent not stated) in unspecified doses. No adverse effects were noted in their infants and normal developmental milestones were reported. ◉ Effects on Lactation and Breastmilk:Reboxetine increased serum prolactin in male subjects. The relevance of this finding to nursing mothers is not clear. The prolactin level in a mother with established lactation may not affect her ability to breastfeed. An observational study looked at outcomes of 2859 women who took an antidepressant during the 2 years prior to pregnancy. Compared to women who did not take an antidepressant during pregnancy, mothers who took an antidepressant during all 3 trimesters of pregnancy were 37% less likely to be breastfeeding upon hospital discharge. Mothers who took an antidepressant only during the third trimester were 75% less likely to be breastfeeding at discharge. Those who took an antidepressant only during the first and second trimesters did not have a reduced likelihood of breastfeeding at discharge. The antidepressants used by the mothers were not specified. A retrospective cohort study of hospital electronic medical records from 2001 to 2008 compared women who had been dispensed an antidepressant during late gestation (n = 575) to those who had a psychiatric illness but did not receive an antidepressant (n = 1552) and mothers who did not have a psychiatric diagnosis (n = 30,535). Women who received an antidepressant were 37% less likely to be breastfeeding at discharge than women without a psychiatric diagnosis, but no less likely to be breastfeeding than untreated mothers with a psychiatric diagnosis. None of the mothers were taking reboxetine. In a study of 80,882 Norwegian mother-infant pairs from 1999 to 2008, new postpartum antidepressant use was reported by 392 women and 201 reported that they continued antidepressants from pregnancy. Compared with the unexposed comparison group, late pregnancy antidepressant use was associated with a 7% reduced likelihood of breastfeeding initiation, but with no effect on breastfeeding duration or exclusivity. Compared with the unexposed comparison group, new or restarted antidepressant use was associated with a 63% reduced likelihood of predominant, and a 51% reduced likelihood of any breastfeeding at 6 months, as well as a 2.6-fold increased risk of abrupt breastfeeding discontinuation. Specific antidepressants were not mentioned.
来源:Drugs and Lactation Database (LactMed)

SDS

SDS:233ef2705b9c57917651dbf58c632558
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Pharmaceutical salts of reboxetine
    申请人:Airoldi Annalisa
    公开号:US20070010517A1
    公开(公告)日:2007-01-11
    The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical corn-positions containing them.
    本发明涉及一种新型结晶的、水溶性的盐,它们是雷贝辛的2S,3S对映体的富马酸盐和琥珀酸盐,涉及其制备过程、在治疗中的应用以及包含它们的制药组合物。
  • PHARMACEUTICAL SALTS OF REBOXETINE
    申请人:Airoldi Annalisa
    公开号:US20090291953A1
    公开(公告)日:2009-11-26
    The present invention relates to novel crystalline, water-soluable salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical compositions containing them.
    本发明涉及一种新型晶体,即2S,3S对映体的reboxetine的水溶性盐,其中包括富马酸盐和琥珀酸盐,以及其制备过程,其在治疗中的应用以及含有它们的制药组合物。
  • FMO3 inhibitors for treating pain
    申请人:Akron Molecules GmbH
    公开号:EP2674161A1
    公开(公告)日:2013-12-18
    The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.
    本发明涉及治疗疼痛和相关疾病的新疗法,以及用于上述疗法的药物化合物。
  • Compounds and Methods for Treating Pain
    申请人:Penninger Josef
    公开号:US20130252924A1
    公开(公告)日:2013-09-26
    The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.
  • COMPOUNDS AND METHODS FOR TREATING PAIN
    申请人:AKRON MOLECULES AG
    公开号:US20140349969A1
    公开(公告)日:2014-11-27
    The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.
查看更多